Business
Annovis Appoints Mark Guerin as Chief Financial Officer
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical developm
About this update from Annovis Bio, Inc.
[{"type":"image","alt":"Annovis Bio Inc.","displaySize":"","headline":null,"caption":"Annovis Bio Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/plvHQ2cwqCYZbJvLkT5mUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200}},"lazy":false},{"type":"text","content":"MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development.","length":522,"tagName":"p"},{"type":"text","content":"Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW), to augment the company’s financial reporting, forecasting, and internal controls following its IPO in July 2013, and was named its CFO in 2016. During his tenure as CFO, Onconova completed several critical financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings. Onconova merged with Trawsfynydd Therapeutics, Inc. in April 2024, with concurrent investments from OrbiMed and Torrey Pines, to form Traws Pharma, Inc. and to advance product candidates of both companies in virology and oncology. The company also completed an additional $20 million financing in December 2024.","length":863,"tagName":"p"},{"type":"text","content":"Prior to joining Onconova, Mr. Guerin worked as an interim senior finance and accounting executive, facilitating post-acquisition integration activities of newly acquired private equity portfolio companies. He also served as Vice President of Finance and CFO at Cardiokine, Inc., overseeing its New Drug Application filing and subsequent sale of the...